An assessment score to predict survival based on clinical and laboratory data in metastatic renal cell carcinoma patients.
To calculate and interpret the total sum for the MSKCC/Motzer score.
The guideline is used to calculate the Total score and/or the interpretation of the calculated Total score in the form of "risk group" and "median survival 4 months" in patients with metastatic renal cell carcinoma undergoing systemic therapy. It can be used to identify patients being considered for clinical trial enrollment, and in clinical practice for the estimation of prognosis. The risk here refers to the risk to survival. The Total score is stratified for risk and median survival as follows: 1. Score: 0, Risk: Good, Median survival: 20 months 2. Score: 1-2, Risk: Intermediate, Median survival: 10 months 3. Score: ≥3, Risk: High, Median survival: 4 months
Not to be used for making decisions about treatment for metastatic renal cell carcinoma.
Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17(8):2530-40. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002 Jan 1;20(1):289-96. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004;22(3):454-63. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584-90.
openEHR-EHR-OBSERVATION.mskcc_motzer, openEHR-EHR-EVALUATION.health_risk
